Reference is made to stock exchange notices dated 4 May 2015 and 7 June 2015 regarding a private placement with proceeds of NOK 37.1 million (the "Private Placement") and a convertible bond loan with proceeds of NOK 67.6 million.
Hofseth BioCare ASA hereby publishes a prospectus related to the listing of 12,373,478 new shares issued in the Private Placement. The Norwegian Financial Supervisory Authority has reviewed and approved the prospectus.
The prospectus is attached to this stock exchange notice and will also be made available at the company's website, www.hofsethbiocare.no. The prospectus is also available at the company's headquarters at Molovegen 6, 6004 Ålesund, Norway.
* * *
For further information, please contact:
Jon Olav Ødegård, CEO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: jon.olav.odegard@hofsethbiocare.no
Øystein Omvik, CFO of Hofseth BioCare ASA
Phone: +47 936 99 400
E-mail: oystein.omvik@hofsethbiocare.no
About Hofseth BioCare:
Hofseth BioCare is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, Hofseth BioCare is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. Hofseth BioCare`s objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.
